Document is current

Article History

Received: 15 November 2021

Accepted: 10 May 2022

First Online: 24 May 2022

Declarations

:

: Ethics approval was obtained from the Health Research Ethics Board – Health Panel at the University of Alberta (Pro00095694). The need for written informed consent was waived by the Health Research Ethics Board - Health Panel ethics committee due to retrospective nature of the study<i>.</i> Sentinel and custodian participants provided the appropriate consent and/or data sharing agreements. A waiver of explicit individual patient consent was approved for NAPCReN to collect de-identified EMR data. All methods were performed in accordance with the relevant guidelines and regulations.

: Not applicable.

: • Dr. Yeung: Personal fees from Merck, personal fees from Diabetes Canada, personal fees from Novo Nordisk, personal fees from Sanofi, grants from Astra Zeneca, grants from Allergen, outside the submitted work.• Dr. Campbell-Scherer: NOVAD (University Hospital Foundation, Novo Nordisk & Alberta Economic Development and Trade), Pfizer - Diabetes and Obesity Expert Advisory Board.• All other authors do not have any competing interests to disclose.